AbbVie’s $2.1 Billion Acquisition of Capstan Therapeutics Signals Strong Commitment to Cancer Research
AbbVie has made a $2.1 billion acquisition of Capstan Therapeutics, positioning itself to lead in cancer research and treatment with cutting-edge tools and technologies.
2 minutes to read